Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database
Abstract Aim Real‐world data (RWD) for paliperidone palmitate (PP) three‐monthly (PP3M) is lacking based on Japan label requirements. This study evaluated the clinical effectiveness of PP3M versus PP once‐monthly (PP1M) in patients with schizophrenia administered according to Japan label requirement...
Saved in:
| Main Authors: | Chih‐Lin Chiang, Madoka Chinen, Mehmet Daskiran, Akihide Wakamatsu, Ibrahim Turkoz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Neuropsychopharmacology Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/npr2.12473 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01) -
BRIVA‐ONE study: 12‐month outcomes of brivaracetam monotherapy in clinical practice
by: Vicente Villanueva, et al.
Published: (2024-12-01) -
Successful treatment with olanzapine and aripiprazole of a schizophrenic patient who developed priapism after switching from risperidone to paliperidone
by: Saki Kawahara, et al.
Published: (2024-12-01) -
Head-to-Head Comparison of UHPLC-MS/MS and Alinity C for Plasma Analysis of Risperidone and Paliperidone
by: Francisco José Toja-Camba, et al.
Published: (2024-10-01) -
A case report of exacerbation of extrapyramidal symptoms following the switch from risperidone to paliperidone during valproate therapy
by: Emi Hata, et al.
Published: (2025-01-01)